 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Event will follow the presentation of INB-100 data in patients with hematologic malignancies at the American Society of Hematology (ASH) 65th Annual Meeting & Exposition on the evening of December...

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and...

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. (NASDAQ:INAB  Free Report)  Equities research analysts at HC Wainwright increased their FY2023 earnings per share estimates for shares of IN8bio in a research note issued...

HC Wainwright Analysts Boost Earnings Estimates for IN8bio, Inc. (NASDAQ:INAB)

IN8bio (NASDAQ:INAB  Get Free Report)s stock had its buy rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on...

IN8bio (NASDAQ:INAB) Given "Buy" Rating at HC Wainwright

Company will present late-breaker poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs...

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number...

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune...

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

This data represents a step forward in developing next-generation 'off-the-shelf' iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential...

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company tackling one of society's most pressing issues: cancer.
read more...

How IN8bio Is Working To Reach Its Goal Of 'Cancer Zero'   Making Cancer A Thing of The Past

New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on durability of responses and...

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Watchers	903
52-Wk Low	$0.65
52-Wk High	$3.95

Market Cap	$27.05M
Volume (M)	4,436.00
52-Wk High	$3.95
52-Wk Low	$0.65

Current Price	$0.8999
Prev Close	$0.8455
Open	$0.8385
Dividend Yield	0.00%
50-Day Moving Average	$0.9622
Beta	0.00
Avg. Volume	201,637.29
PE Ratio	-0.75

52-Week High	$3.95
52-Week Low	$0.65
Market Capitalization	$27.05M
EPS	-$1.12
Price to Book	1.52
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-0.89

INAB IN8bio Inc

About

Feed

News

Earnings

Fundamentals